ArticleNAR cancer2026
EXO1 inhibition selectively kills replication repair-deficient cancer cells.
Article in NAR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deficiencies in DNA repair pathways create context-specific vulnerabilities that may be exploited therapeutically. Recent studies have established EXO1 as a druggable nuclease, but the genetic contexts that confer sensitivity to EXO1 inhibition remain incompletely defined. Here, we assessed whether pharmacological inhibition of EXO1 selectively targets repair-deficient cancer cells across multiple DNA repair backgrounds. Using potent and selective EXO1 inhibitors, we demonstrate impaired viability in cells deficient for Fanconi Anaemia pathway components (FANCG and APITD1/MHF1), BRCA1-A complex factor BRCC36, and the spliceosome factor ZRSR2. EXO1 inhibition in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.